Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Oral Drug Approved for Spinal Muscular Atrophy

Oral Drug Approved for Spinal Muscular Atrophy News & Analysis News From the Food and Drug Administration CBD Drug Is Approved for a Third Form health risks from chronic dietary exposure food production and plan to monitor PFAS of Epilepsy to the chemicals, FDA officials said. The levels in the food supply. A drug containing the marijuana derivative data pertain to short-chain PFAS that con- cannabidiol (CBD) was approved to treat sei- tain 6:2 fluorotelomer alcohol (6:2 FTOH), Oral Drug Approved for Spinal zures associated with tuberous sclerosis which the agency noted may migrate to Muscular Atrophy complex (TSC) in patients aged 1 year or food and cannot be removed by washing The first oral therapy for adults and chil- older.TSCisageneticdiseasethatcausesbe- or cooking. dren aged 2 months or older who have spinal muscular atrophy (SMA) has received nign tumors to grow throughout the body. It affects 1 in 6000 people. FDA approval. A fatal genetic disease that leads to The drug, marketed as Epidiolex, is the only FDA-approved drug with CBD as an severe muscle weakness, SMA affects about 1 in 8000 to 10 000 people world- active ingredient. It was approved in 2018 to treat seizures in patients with Dravet or wide. Infants with SMA http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Oral Drug Approved for Spinal Muscular Atrophy

Jaklevic, Mary Chris
JAMA , Volume 324 (11) – Sep 15, 2020
Download PDF
1 page

Oral Drug Approved for Spinal Muscular Atrophy

Abstract

News & Analysis News From the Food and Drug Administration CBD Drug Is Approved for a Third Form health risks from chronic dietary exposure food production and plan to monitor PFAS of Epilepsy to the chemicals, FDA officials said. The levels in the food supply. A drug containing the marijuana derivative data pertain to short-chain PFAS that con- cannabidiol (CBD) was approved to treat sei- tain 6:2 fluorotelomer alcohol (6:2 FTOH), Oral Drug Approved for Spinal zures associated with...
Loading next page...
 
/lp/american-medical-association/oral-drug-approved-for-spinal-muscular-atrophy-sFOfq0bg8R

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2020.16783
Publisher site
See Article on Publisher Site

Abstract

News & Analysis News From the Food and Drug Administration CBD Drug Is Approved for a Third Form health risks from chronic dietary exposure food production and plan to monitor PFAS of Epilepsy to the chemicals, FDA officials said. The levels in the food supply. A drug containing the marijuana derivative data pertain to short-chain PFAS that con- cannabidiol (CBD) was approved to treat sei- tain 6:2 fluorotelomer alcohol (6:2 FTOH), Oral Drug Approved for Spinal zures associated with tuberous sclerosis which the agency noted may migrate to Muscular Atrophy complex (TSC) in patients aged 1 year or food and cannot be removed by washing The first oral therapy for adults and chil- older.TSCisageneticdiseasethatcausesbe- or cooking. dren aged 2 months or older who have spinal muscular atrophy (SMA) has received nign tumors to grow throughout the body. It affects 1 in 6000 people. FDA approval. A fatal genetic disease that leads to The drug, marketed as Epidiolex, is the only FDA-approved drug with CBD as an severe muscle weakness, SMA affects about 1 in 8000 to 10 000 people world- active ingredient. It was approved in 2018 to treat seizures in patients with Dravet or wide. Infants with SMA

Journal

JAMA – American Medical Association

Published: Sep 15, 2020

There are no references for this article.